Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan D Richman

Showing results (1-10 of 45) with videos related to

Pageof 5
Sort By:
Virchows Archiv : an International Journal of Pathology|June 28, 2017
RAS screening in colorectal cancer: a comprehensive analysis of the results from the UK NEQAS colorectal cancer external quality assurance schemes (2009-2016)Susan D Richman, Jennifer Fairley, Rachel Butler, et al.
Journal of Clinical Pathology|September 30, 2016
How close are we to standardised extended RAS gene mutation testing? The UK NEQAS evaluationSusan D Richman, Jennifer Fairley, Rachel Butler, et al.
The Lancet. Oncology|March 21, 2002
Prediction of the response of colorectal cancer to systemic therapyJulian W Adlard, Susan D Richman, Matthew T Seymour, et al.
Analytical Cellular Pathology (Amsterdam)|April 13, 2011
Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testingSusan D Richman, Philip Chambers, Matthew T Seymour, et al.
Molecular Diagnosis & Therapy|February 12, 2019
Targeted Next-Generation Sequencing Validates the Use of Diagnostic Biopsies as a Suitable Alternative to Resection Material for Mutation Screening in Colorectal CancerHersh A Ham-Karim, Henry Okuchukwu Ebili, Kirsty Manger, et al.
Pathology, Research and Practice|June 3, 2019
Targeted next generation sequencing reveals a common genetic pathway for colorectal cancers with chromosomal instability and those with microsatellite and chromosome stabilityHersh A Ham-Karim, Henry O Ebili, Kirsty Bradshaw, et al.
Journal of Clinical Pathology|July 22, 2018
Results of the UK NEQAS for Molecular Genetics reference sample analysisSusan D Richman, Jennifer Fairley, Jacqueline A Hall, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2009
KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trialSusan D Richman, Matthew T Seymour, Philip Chambers, et al.
JAMA Oncology|February 13, 2016
Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal CancerJenny F Seligmann, Faye Elliott, Susan D Richman, et al.
Cells|October 15, 2025
Multiplexed Digital PCR Reference Gene Measurement for Genomic and Cell-Free DNA AnalysisDilek Yener, Eloise J Busby, Jo Vandesompele, et al.
Pageof 5

Showing results (1-10 of 45) with videos related to

Sort By:
Pageof 5
Virchows Archiv : an International Journal of Pathology|June 28, 2017
RAS screening in colorectal cancer: a comprehensive analysis of the results from the UK NEQAS colorectal cancer external quality assurance schemes (2009-2016)Susan D Richman, Jennifer Fairley, Rachel Butler, et al.
Journal of Clinical Pathology|September 30, 2016
How close are we to standardised extended RAS gene mutation testing? The UK NEQAS evaluationSusan D Richman, Jennifer Fairley, Rachel Butler, et al.
The Lancet. Oncology|March 21, 2002
Prediction of the response of colorectal cancer to systemic therapyJulian W Adlard, Susan D Richman, Matthew T Seymour, et al.
Analytical Cellular Pathology (Amsterdam)|April 13, 2011
Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testingSusan D Richman, Philip Chambers, Matthew T Seymour, et al.
Molecular Diagnosis & Therapy|February 12, 2019
Targeted Next-Generation Sequencing Validates the Use of Diagnostic Biopsies as a Suitable Alternative to Resection Material for Mutation Screening in Colorectal CancerHersh A Ham-Karim, Henry Okuchukwu Ebili, Kirsty Manger, et al.
Pathology, Research and Practice|June 3, 2019
Targeted next generation sequencing reveals a common genetic pathway for colorectal cancers with chromosomal instability and those with microsatellite and chromosome stabilityHersh A Ham-Karim, Henry O Ebili, Kirsty Bradshaw, et al.
Journal of Clinical Pathology|July 22, 2018
Results of the UK NEQAS for Molecular Genetics reference sample analysisSusan D Richman, Jennifer Fairley, Jacqueline A Hall, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2009
KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trialSusan D Richman, Matthew T Seymour, Philip Chambers, et al.
JAMA Oncology|February 13, 2016
Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal CancerJenny F Seligmann, Faye Elliott, Susan D Richman, et al.
Cells|October 15, 2025
Multiplexed Digital PCR Reference Gene Measurement for Genomic and Cell-Free DNA AnalysisDilek Yener, Eloise J Busby, Jo Vandesompele, et al.
Pageof 5